| In Vitro | In vitro activity: In vitro, Tauroursodeoxycholate shows protective and reversing effects on 17βEG-induced impairment of the cVA-of-CLF. In Mz-ChA-1 cholangiocarcinoma cells, Tauroursodeoxycholate inhibits cell growth via Ca2+-, PKC-, and MAPK-dependent pathways. In isolated rat hepatocytes, Tauroursodeoxycholate inhibits bile acid-Induced Apoptosis via a β1-integrin-mediated formation of cAMP.
Cell Assay: After trypsinization, Mz-ChA-1 cells are suspended in CCM at 5 × 104 cells/mL, and 200 μL of the cell suspension are seeded into flat-bottomed 96-well plates. After an initial incubation step of 4 h at 37°C in a 5% CO2 incubator, the cells are incubated at 37°C with TUDCA (0.2–200 μM). After incubation for 24–96 h, [3H]thymidine is put into each well at 5.0 μCi/mL and incubated for additional 4 h. [3H]thymidine incorporation is measured by a scintillation counter. At the end of each incubation period, cell viability is evaluated by trypan blue exclusion. |
|---|
| In Vivo | In phalloidin-induced cholestasis rats, Tauroursodeoxycholate (360 μmol/kg, i.v.) significantly suppresses the decrease in bile flow and increases in serum alkaline phosphatase, leucine aminopeptidase and glutamic pyruvic transaminase activities, cholesterol, phospholipid and bile acid concentrations. |
|---|
